News coverage about GTX (NASDAQ:GTXI) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. GTX earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 44.2433178434088 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
GTXI has been the topic of a number of research analyst reports. Stifel Nicolaus initiated coverage on shares of GTX in a report on Thursday, November 9th. They issued a “buy” rating on the stock. Robert W. Baird initiated coverage on shares of GTX in a report on Tuesday, November 21st. They issued an “outperform” rating and a $17.00 price target on the stock. Finally, Zacks Investment Research lowered shares of GTX from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th.
Shares of GTX (NASDAQ GTXI) traded up $0.34 during trading hours on Thursday, hitting $12.50. 69,900 shares of the stock were exchanged, compared to its average volume of 61,036. The company has a market cap of $271.75, a price-to-earnings ratio of -7.14 and a beta of 1.77. GTX has a 1 year low of $2.73 and a 1 year high of $13.35.
In other news, VP Henry Patton Doggrell sold 4,965 shares of the company’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $11.33, for a total value of $56,253.45. Following the completion of the sale, the vice president now owns 54,804 shares of the company’s stock, valued at approximately $620,929.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jason T. Shackelford sold 3,090 shares of the company’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $11.33, for a total transaction of $35,009.70. Following the completion of the sale, the insider now directly owns 31,111 shares of the company’s stock, valued at approximately $352,487.63. The disclosure for this sale can be found here. Insiders sold a total of 15,364 shares of company stock worth $174,074 in the last three months. Insiders own 41.20% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “GTX (GTXI) Getting Somewhat Favorable Press Coverage, Report Shows” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/3144231/gtx-gtxi-getting-somewhat-favorable-press-coverage-report-shows.html.
GTX Company Profile
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.